Wikipedia

Mark Kendall (engineer)

Mark A. F. Kendall (BE PhD FTSE FRSA FNAI) (born 1972) is an Australian biomedical engineer, inventor, scientist and entrepreneur.

Mark Kendall
Born (1972-04-16) 16 April 1972 (age 52)
NationalityAustralian
OccupationBiomedical engineer
EmployerAustralian National University
Known forBiomedical invention

He is Founder and CEO of WearOptimo Pty Ltd[1] and the Vice-Chancellor's Entrepreneurial Professor at the Australian National University.[2]

Kendall was formerly the Professor of Biomedical Engineering at the University of Queensland, where he led a team at the Australian Institute for Bioengineering and Nanotechnology[citation needed]. He was Founder, CTO and a Director of Vaxxas[citation needed]. Prior to this, in the UK, he was a University Research Lecturer at the University of Oxford and a lecturer at Magdalen College, Oxford[citation needed]. Whilst at Oxford, Kendall was Associate Director of the PowderJect Research Centre for Gene and Drug Delivery[citation needed].

Kendall serves at the co-chair of the $150 million Australian Stem Cell Therapies Mission[3] and on the World Economic Forum Global Future Council on Biotechnology.[4]

Kendall has filed more than 160 patents (including territories)[citation needed], published in excess of 300 papers[citation needed], licensed his technologies seven times (including to Merck & Co.)[citation needed] and partnered globally, including with the World Health Organization, and the Bill & Melinda Gates Foundation.[5] The biotech enterprises he has founded or made significant contribution to have generated in the region of $2 billion Aus in value[citation needed].

Kendall's contributions to innovation in global healthcare has been recognised with more than forty awards. These include recent elections as:

• World Economic Forum Technology Pioneer (2015).[6]

• Fellow of ATSE; Australian Academy of Technological Sciences and Engineering (2017).[7]

• Fellow of the Royal Society for the encouragement of Arts, Manufacture and Commerce (now the RSA), UK; (2017)[citation needed].

Kendall is a CSL Young Florey Medallist[8] and Rolex Laureate.[9][10]

Kendall's work regularly features in international media, including on the National Geographic Channel.[11]

Kendall's TedGlobal talk has been viewed more than a million times.[12]

https://www.ted.com/speakers/mark_kendall

Background edit

Kendall was born on 16 April 1972.[13] He received his Bachelors of Engineering (Hons I, 1993) and PhD (1998) from the University of Queensland.[14]

In 1998, Kendall moved to the UK to take up a position in the Department of Engineering Science at the University of Oxford (1998-2006). He has subsequently held positions at the University of Queensland (2006-2018)[citation needed] and at the Australian National University (2018–Present)[citation needed].

Contributions to Biotechnology edit

Kendall has over 160 patent applications of which[citation needed], 128 have been granted to date[citation needed]. He has authored more than 300 refereed papers[citation needed].

At the University of Oxford[14] (1998-2006) Kendall developed a biolistic technique for the delivery of vaccines directly into the skin without the use of needles.

At the University of Queensland (2006-2018) Kendall invented the Nanopatch[15][16] for needle-free delivery of vaccines.[17][18]

At WearOptimo[19] and the Australian National University[20] (2018 to present), Kendall has invented the Microwearable™[21][22] sensor for personalised medicine.

During his career, Kendall has collaborated with major global health partners including the Bill & Melinda Gates Foundation,[23] World Health Organization[24][25] and Merck & Co.[26]

He is an Australian Government Academy of Science COVID-19 Expert.[27]

Selected Awards, Honours and Prizes edit

  • Elected to the World Economic Forum Global Future Council on Biotechnology (2019 to present).[28]
  • Elected Fellow of the Australian Academy of Technology and Engineering ATSE (2017).[7]
  • Elected Fellow of the Royal Society for the encouragement of Arts, Manufacture and Commerce (now the RSA), UK (2017)[citation needed].
  • Elected to the World Economic Forum Global Future Council on Entrepreneurship and Innovation (2016-2018)[citation needed].
  • CSL Young Florey Medal (2016).[29][30][31]
  • Dr John Dixon Hughes Medal for Medical Research Innovation (2016).[32]
  • World Economic Forum Technology Pioneer (2015).[33]
  • Rolex Laureate Award for Enterprise (2012) for his "pioneering efforts to expand knowledge and improve human life".[34]
  • 2011 Australian Innovation Challenge winner.[35]
  • 2011 Eureka Prize for Interdisciplinary Research.[35]
  • 2010 Merck Translational Research Excellence Commercialisation Award.[36]
  • 2005 Best Medical Innovation Award (Popular Science magazine)[citation needed].
  • Younger Engineer of Great Britain (2004).[citation needed]

Contributions to biotech companies edit

As Associate Director of the Oxford University PowderJect Research Centre (2000-2006)[citation needed], Kendall advanced biolistics technology[citation needed], commercialised with PowderJect[citation needed], purchased by Chiron (later Novartis) in 2003[citation needed]; and then with PowderMed, purchased by Pfizer in 2006[citation needed].

Kendall founded Vaxxas in 2011 to advance his Nanopatch[15] technology for global impact, securing more than $40 million of investment, in the series A ($15m)[37] and B (in excess of $25m) rounds.[38] The Nanopatch technology has been licensed to Merck & Co. He served as the Vaxxas Chief Technology Officer, Director, and Chair of the Vaxxas Advisory Board (2011-2015).

In 2018, Kendall founded WearOptimo[39] where he serves as CEO.

References edit

  1. ^ "Home | WearOptimo | Microwearable devices | Australia". WearOptimo / to edit. Retrieved 8 June 2020.
  2. ^ "ANU welcomes funding for wearable medical technology". ANU. 16 May 2018. Retrieved 8 June 2020.
  3. ^ Hunt, Greg (13 March 2019). "Australian Stem Cell Therapies Mission". Retrieved 8 June 2020.
  4. ^ WEF. "Future of Biotechnology". World Economic Forum. Retrieved 8 June 2020.
  5. ^ "After 160 years, it's time to move on from the needle and syringe". www.scienceinpublic.com.au. Retrieved 8 June 2020.
  6. ^ "Authors". World Economic Forum. Retrieved 8 June 2020.
  7. ^ a b "Mark Kendall elected as a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE)". CBNS. 17 October 2017. Retrieved 8 June 2020.
  8. ^ Australian Institute of, Policy and Science (27 April 2020). "Young Florey Medal". Retrieved 9 June 2020. {{cite web}}: |first= has generic name (help)
  9. ^ "Fear of Needles? There's New Tech on the Way". National Geographic News. 14 November 2016. Archived from the original on 8 June 2020. Retrieved 8 June 2020.
  10. ^ "5 Times Rolex Helped to Make the World a Better Place". Time and Tide Watches. 27 September 2016. Retrieved 8 June 2020.
  11. ^ "Fear of Needles? There's New Tech on the Way". National Geographic News. 14 November 2016. Archived from the original on 8 June 2020. Retrieved 10 June 2020.
  12. ^ Kendall, Mark. "Mark Kendall | Speaker | TED". www.ted.com. Retrieved 8 June 2020.
  13. ^ "Mark Kendall: Profile". Rolex Awards for Enterprise. Retrieved 10 June 2016.
  14. ^ a b Scott, Leisa (30 November 2013). "Professor Mark Kendall, 41, biomedical engineer/inventor". The Courier-Mail. Retrieved 10 June 2016.
  15. ^ a b Council, Australian Research (5 June 2018). "Nanopatch—Revolutionising treatment of disease across the globe". www.arc.gov.au. Retrieved 10 June 2020.
  16. ^ "UQ technology with the power to revolutionise global vaccine delivery". UniQuest. Retrieved 10 June 2020.
  17. ^ Vidal, John (26 December 2012). "Vaccine patch offers pain-free way to stop disease in Papua New Guinea | John Vidal". The Guardian. ISSN 0261-3077. Retrieved 10 June 2020.
  18. ^ ""Nanopatch" Administers Vaccines Painlessly". National Geographic Society Newsroom. 26 November 2012. Archived from the original on 10 June 2020. Retrieved 10 June 2020.
  19. ^ "About | WearOptimo | Established by Professor Mark Kendall | Brisbane Australia". WearOptimo / to edit. Retrieved 9 June 2020.
  20. ^ "WearOptimo and ANU: towards a healthcare future within the fourth industrial revolution". ANU. 2 October 2018. Retrieved 8 June 2020.
  21. ^ "WearOptimo headquarters open in Brisbane". ANU. 29 March 2019. Retrieved 8 June 2020.
  22. ^ "Our Tech | WearOptimo | Microwearable devises | Australia". WearOptimo / to edit. Retrieved 9 June 2020.
  23. ^ "Nanopatch Delivery of DNA-Based Malaria Vaccines to Skin: Precisely Targeting the Skin Immune System for Radically Improved Vaccines | Grand Challenges". gcgh.grandchallenges.org. Retrieved 9 June 2020.
  24. ^ "Nanopatch polio vaccine delivers". ScienceDaily. Retrieved 9 June 2020.
  25. ^ "Nanopatch creator Mark Kendall". Science Meets Business. 24 April 2017. Retrieved 9 June 2020.
  26. ^ Council, Australian Research (19 July 2018). "ARC Future Fellow pioneers needle-free immunisation for the world". www.arc.gov.au. Retrieved 9 June 2020.
  27. ^ "Expert - Mark Kendall | Australian Academy of Science". www.science.org.au. Retrieved 8 June 2020.
  28. ^ "The Future of Biotechnology". World Economic Forum. Retrieved 10 June 2020.
  29. ^ "Professor Mark Kendall wins the 2016 CSL Young Florey Medal". CBNS. 11 November 2016. Retrieved 10 June 2020.
  30. ^ "2016 – Professor Mark Kendall – AIPS". Retrieved 10 June 2020.
  31. ^ "Media Kit – 2016 CSL Young Florey Medal". www.scienceinpublic.com.au. Retrieved 10 June 2020.
  32. ^ "Previous Medal Winners - NFMRINFMRI". Retrieved 10 June 2020.
  33. ^ "4 things Australia needs to know about innovation". World Economic Forum. Retrieved 10 June 2020.
  34. ^ "Researchers: Professor Mark Kendall". Australian Institute for Bioengineering and Nanotechnology. Retrieved 10 June 2016.
  35. ^ a b Council, Australian Research (19 July 2018). "ARC Future Fellow pioneers needle-free immunisation for the world". www.arc.gov.au. Retrieved 10 June 2020.
  36. ^ "Nanotechnology Now - Press Release: Needle-free vaccine technology a step closer to clinical trials". www.nanotech-now.com. Retrieved 10 June 2020.
  37. ^ Queensl, The University of; Lucia, Australia Brisbane St; Gatton, QLD 4072 +61 7 3365 1111 Other Campuses: UQ; Maps, UQ Herston; Queensl, Directions © 2020 The University of. "New vaccine delivery company starts with AUD15 million investment". UQ News. Retrieved 9 June 2020.{{cite web}}: CS1 maint: numeric names: authors list (link)
  38. ^ Queensl, The University of; Lucia, Australia Brisbane St; Gatton, QLD 4072 +61 7 3365 1111 Other Campuses: UQ; Maps, UQ Herston; Queensl, Directions © 2020 The University of. "Nanopatch vaccine technology company attracts $25 million". UQ News. Retrieved 8 June 2020.{{cite web}}: CS1 maint: numeric names: authors list (link)
  39. ^ "Home | WearOptimo | Microwearable devices | Australia". WearOptimo / to edit. Retrieved 10 June 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mark_Kendall_(engineer)&oldid=1186572315"